Knight Initiative News

With Knight Initiative support, Stanford researchers uncover a biochemical “off-ramp” in ketosis, rewriting our understanding of how ketosis influences metabolism.

Today, we are going back into the archives for a conversation with neuroscientist, entrepreneur, and best-selling author David Eagleman about the science of synesthesia. If you don't know what that is, you're about to find out.

Bioengineers and neuroscientists at the Wu Tsai Neurosciences Institute at Stanford University have developed a highly sensitive tool for detecting brain cells’ subtlest electrical signals.

Science Corporation's retinal implant, built on the research of faculty affiliate Daniel Palanker, has allowed some people who lost their central vision to read, play cards, and recognize faces.

This week, we talk with our founding director, Bill Newsome, about the 10-year legacy of the NIH BRAIN Initiative and the uncertainty for the future brought on by this year's dramatic funding cuts.

This week we are talking with Stanford neuroscientist Ivan Soltesz about endocannabinoids, illuminating the "day job" of these unusual neurotransmitters and how they may be hijacked by cannabinoid drugs such as THC and CBD.

Supported by the Big Ideas in Neuroscience program, research from the Brunet lab suggests the possibility of designing pharmaceutical or genetic therapies to turn on new neuron production in old or injured brains.

Laura Gwilliams, a Wu Tsai Neuro faculty scholar, and Brian Hie are the inaugural faculty of Stanford Data Science. Their work spans multiple disciplines but is united by the desire to explore and leverage large volumes of real-world data.

Work on human cognition by the founding director of the Wu Tsai Neuro Center for Mind, Brain, Computation and Technology was foundational for neural-network-based computational modeling 

This week we are talking with Stanford neurobiologist Lisa Giocomo, exploring the intersection of memory, navigation, and the boundaries we create between ourselves and the world around us.

Wu Tsai Neuro affiliate Carolyn Rodriguez directs the Stanford OCD Research Lab. She tells NPR there are still a lot of basics we have yet to understand about OCD.

Stanford undergraduates and local community college students showcased their summer research projects at the Wu Tsai Neurosciences Institute, highlighting efforts to introduce students to neuroscience research for the first time.

With support from a Wu Tsai Neuro seed grant, faculty affiliate Helen Bronte-Stewart and her team have developed a simple, portable device to help Parkinson's patients track their symptoms at home.

The 2024 NeuroTech trainees at Wu Tsai Neuro are advancing neurotechnology through interdisciplinary research and collaboration, combining expertise from fields like bioengineering, computer science, and electrical engineering.

Introducing the 2024 MBCT student members, PhD students advancing neuroscience through interdisciplinary research that spans psychology, biology, engineering, and more.

Meet the 2024 Stanford Interdisciplinary Graduate Fellows supported by the Wu Tsai Neurosciences Institute who are driving cutting-edge, interdisciplinary neuroscience research.

As summer draws to a close, I’m excited to welcome you all to the new academic year. With much to look forward to in the months ahead—from our annual symposium on the intersection of neuroscience and AI to the relaunch of our Big Ideas grant program—I’d first like to take a moment to reflect on the progress we’ve made together.

The Knight Initiative for Brain Resilience supports 14 high-risk, high-reward projects to advance brain health and resilience research, fostering bold research across various scientific disciplines.

Research projects funded by the Wu Tsai Neurosciences Institute's Synthetic Neuroscience Grants will advance molecular and tissue engineering tools to more precisely study and interact with brain circuits.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.